We have incorporated the 9m 22 numbers into our estimates. In line with the strong increase in revenues observed over 9 months (+64%) for CMS and the management's outlook of €120m in 2023 for the division, we have revised our revenue estimates upwards to €83m from €78m for 2022 and to €121m from €91m for 2023. Our margin estimates are now €4.2m and €9.6m for 2022 and 2023 respectively. We have also revised upwards the figures for CFT, which is not yet experiencing the slowdown we had expected (+49% over 9m), and we now estimate revenues of €224m in 2022, compared to €193m and operational profit of €14.6m (versus €12.5m) in 2022. Concerning CPC, our estimates of €28.4m for 2022 were too ambitious in view of the strong setback owing to the health crisis in Europe, so we now expect turnover of €6.4m and a margin of €1.9m. We have also revised downwards the turnover of CAM which is experiencing a reduction in volumes despite the positive price effect, to €343m with a margin of 7% at €24m. Finally, CFL has also been revised downwards to €95m from €108m. All these changes have led to a decrease in our revenue estimates to €752m in 2022 (compared to €775m previously) and €827m in 2023 (compared to €831m previously) as well as in operating profit to €40m in 2022 (compared to €48m) and €53m in 2023 (compared to €60m), which has weighed on our EPS estimates in 2022 and 2023.